The company announced positive Phase 3 trial results for its drug Ziihera, showing significant improvements in progression-free and overall survival for HER2-positive gastroesophageal adenocarcinoma patients when combined with chemotherapy. This breakthrough has generated renewed investor attention and has already powered notable positive momentum in the company's share price. Furthermore, the company is strengthening its position in the medical cannabis market through rising sales of Epidiolex and its broad drug portfolio.